zhengkai Liao

Dr. zhengkai Liao

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 May 2023 in Frontiers in Oncology
Verified
Journal Article
Open access
RFRuoxin Fang
Ruoxin Fang
LYLing Yan
Ling Yan
ZLzhengkai Liao
zhengkai Liao
Cancer-associated cachexia (CAC) is a major characteristic of advanced cancer, associates with almost all types of cancer. Recent studies have found that lipopenia is an important feature of CAC, and it even occurs earlier than sarcopenia. Different types of adipose tissue are all important in the process of CAC. In CAC patients, the catabolism of white adipose tissue (WAT) is increased, leading to an increase in circulating free fatty acids (FFAs), resulting in “ lipotoxic”. At the same time, WAT also is induced by a variety of mechanisms, browning into brown adipose tissue (BAT). BAT is activated in CAC and greatly increases energy expenditure in patients. In addition, the production of lipid is reduced in CAC, and the cross-talk between adipose tissue and other systems, such as muscle tissue and immune system, also aggravates the progression of CAC. The treatment of CAC is still a vital clinical problem, and the abnormal lipid metabolism in CAC provides a new way for the treatment of CAC. In this article, we will review the mechanism of metabolic abnormalities of adipose tissue in CAC and its role in treatment.

13 March 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
LFLimei Fan
Limei Fan
MTMuyou Tian
Muyou Tian
YLYunyi Liu
Yunyi Liu
YDYing Deng
Ying Deng
ZLzhengkai Liao
zhengkai Liao
JXJinhua Xu
Jinhua Xu
Salicylate •Phenanthroline copper (II) complex induces apoptosis in triple-negative breast cancer cells

10 September 2025 in Redox Biology
Verified
Journal Article
Open access
YLYi Liu
Yi Liu
YYYou Yu
You Yu
ZLZhihong Luo
Zhihong Luo
RFRuoxin Fang
Ruoxin Fang
XZXiaodong Zhang
Xiaodong Zhang
WLwenhua li
wenhua li
Ferroptosis, a recently characterized form of regulated cell death driven by iron-dependent lipid peroxidation, has emerged as a promising therapeutic strategy for cancer treatment due to its potential for selectively targeting cancer cells. Exploiting FDA-approved drugs to induce ferroptosis offers a novel approach that exploits cancer cells' vulnerabilities in iron metabolism and oxidative stress. Here, we identify artesunate, an antimalarial drug, as a potent inducer of ferroptosis in gastric cancer cells and reveal the transferrin receptor (TFRC) as a key mediator in this process. Notably, our study is the first to demonstrate an interaction between artesunate and TFRC through molecular docking and surface plasmon resonance (SPR) experiments, highlighting a novel mechanism by which artesunate stabilizes TFRC by inhibiting its lysosomal degradation. This stabilization is regulated via the heat shock protein HSPA9, another previously unreported interaction. Disrupting the TFRC-HSPA9 interaction facilitates iron accumulation and lipid peroxidation, hallmark features of ferroptosis, leading to significant cancer cell death. Additionally, in vivo studies confirm artesunate's anti-tumor efficacy, showing marked tumor growth inhibition and minimal systemic toxicity. These findings underscore the therapeutic relevance of targeting ferroptosis in cancer, particularly by leveraging TFRC's role in iron homeostasis. Furthermore, this study expands the understanding of post-translational regulation in ferroptosis, offering a new perspective on the role of artesunate in cancer therapy.

26 February 2015 in Molecular and Clinical Oncology
Verified
Journal Article
Open access
PDF file
MTMuyou Tian
Muyou Tian
YZYahua ZHONG
Yahua ZHONG
ZFZhou Fuxiang
Zhou Fuxiang
CXConghua Xie
Conghua Xie
YZYunfeng Zhou
Yunfeng Zhou
ZLzhengkai Liao
zhengkai Liao
The aim of the present study was to evaluate the effect of platinum‑based therapy on the short‑term efficacy and survival rate in patients with triple‑negative breast cancer (TNBC). A search of available databases was conducted, based on specific inclusion and exclusion criteria, for trials conducted between January 2006 and January 2014. The bibliographies of the included studies were examined with the same criteria. Included studies were evaluated using Grading of Recommendations Assessment, Development and Evaluation (GRADE), and extracted data were analyzed using RevMan 5.1 and GRADEprofiler 3.6. Eight studies with a total of 1,349 patients were included. The meta‑analysis revealed that the pathological complete response rate and overall response rate in TNBC patients who were treated with a platinum‑based regimen was significantly higher than that in those treated with a non‑platinum‑based regimen (49.2 and 64.3%, respectively). The disease‑free survival rate and overall survival rate were not significantly different between TNBC patients treated with a platinum‑based regimen and those treated with a non-platinum-based regiment (P>0.05). Platinum‑based chemotherapy in TNBC patients resulted in improved short‑term efficacy. Platinum-based regimens may therefore be more sensitive to TNBC patients. However, future multicenter randomized controlled trials are required to validate these findings and to determine whether platinum‑based chemotherapy can extend the survival rate of TNBC patients.

26 March 2015 in Oncology Letters
Verified
Journal Article
Open access
PDF file
MTMuyou Tian
Muyou Tian
YZYahua Zhong
Yahua Zhong
FZFuxiang Zhou
Fuxiang Zhou
CXConghua Xie
Conghua Xie
YZYunfeng Zhou
Yunfeng Zhou
ZLzhengkai Liao
zhengkai Liao
The present meta-analysis aimed to evaluate the effect of neoadjuvant chemotherapy on pathological complete response (pCR) and survival rate in patients with triple-negative breast cancer (TNBC). Specific inclusion and exclusion criteria were used to conduct a search of the available databases, in order to find studies performed between January 2006 and January 2014. The bibliographies of the included studies were examined with the same criteria. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group framework was used to evaluate the included studies, and RevMan 5.1 and GRADEprofiler 3.6 were used to analyze the extracted data. A total of 19 studies with 6,180 patients were included. The meta-analysis revealed that the pCR rates in patients with TNBC were significantly higher than those in patients with non-TNBC. The 5-year disease-free survival (DFS) and overall survival (OS) rates were significantly lower in the patients with TNBC compared with those with non-TNBC. Furthermore, these survival rates were significantly higher in the patients with TNBC who achieved a pCR compared with those in the patients who did not achieve a pCR. pCR rates were higher among the patients with TNBC with high Ki-67 expression than among those with low Ki-67 expression. The patients with TNBC exhibited lower survival rates compared with those with non-TNBC, but achieved higher pCR rates. Moreover, those patients achieving a pCR exhibited improved 5-year survival rates, suggesting that the pCR rate could be predictive of survival in patients with TNBC. In addition, high Ki-67 expression may predict the likelihood of a pCR. However, future multicenter randomized controlled trials are required to enhance the quantity and quality of the clinical evidence.

26 June 2024 in International Journal of Surgery
Verified
Journal Article
Open access
LXLingling Xia
Lingling Xia
WSWei Shi
Wei Shi
YCYuxin Cai
Yuxin Cai
ZLzhengkai Liao
zhengkai Liao
ZHZhen Huang
Zhen Huang
YCYongshun Chen
Yongshun Chen
Background: For stage T1b-2N0-1 esophageal cancer, the impact of neoadjuvant therapy plus surgery (NS), surgery alone (SA), and surgery plus adjuvant therapy (ST) on cancer-specific survival (CSS) and overall survival (OS) is uncertain. Methods: Stage T1b-2N0-1 esophageal cancer patients from the SEER database and two Chinese cancer centers were included in this study. The Kaplan–Meier method was used to plot survival curves, which were compared using the log-rank test. Propensity score matching was used to equalize differences between the groups. Cox proportional hazards regression models were used to analyze prognostic factors. A nomogram for OS was developed after screening the variables using the Cox proportional hazards regression model and the least absolute shrinkage and selection operator. The performance of the nomogram was assessed by the Harrell concordance index (C-index), the area under the curve (AUC) of the receiver operating characteristic curve, calibration plots, and decision curve analysis. Results: After propensity score matching analysis, the 3-year CSS and OS rates in the NS group compared to the SA group were 80.3% versus 62.1% ( P =0.016) and 75.8% versus 55.5% ( P =0.006), the 3-year CSS and OS rates in the NS group compared to the ST group were 71.3% versus 68.3% ( P =0.560) and 69.8% versus 62.9% ( P =0.330), the 3-year CSS and OS rates in the SA group compared to the ST group were 54.6% versus 66.7% ( P =0.220) and 50.2% versus 57.9% ( P =0.290), respectively. The predictive nomogram for OS in T1b-2N0-1 patients ultimately incorporated five clinicopathological variables: T stage, N stage, age, examined lymph nodes, and therapy modality. The nomogram C-index for predicting OS was 0.648, 0.663, and 0.666 in the training group, external validation group-1, and external validation group-2, respectively. The 1-year, 3-year, and 5-year predicted AUC values of the OS prediction model were 0.659, 0.639, and 0.612 for the training group, and 0.786, 0.758, and 0.692 for validation group-1, and 0.805, 0.760, and 0.693 for validation group-2, respectively. Conclusion: For patients with stage T1b-2N0-1 esophageal cancer, neoadjuvant therapy significantly improves prognosis compared to surgery alone, those presenting with positive lymph nodes after upfront surgery can achieve survival benefits from adjuvant therapy.